Self-management of Sedative Therapy by Ventilated Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02819141|
Recruitment Status : Recruiting
First Posted : June 30, 2016
Last Update Posted : February 13, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Critical Illness Anxiety Respiratory Failure||Drug: Dexmedetomidine||Phase 2 Phase 3|
The overall objective of this study is to demonstrate efficacy for conducting a future, pragmatic effectiveness trial to test whether self-management of sedative therapy (SMST) is superior to nurse-administered sedative therapy in day-to-day intensive care unit (ICU) practice. This efficacy trial is powered for the investigators primary, clinically relevant endpoints (anxiety, duration of mechanical ventilation, and delirium presence), and examines patient outcomes adversely affected by sedative administration practices, such as prolonged ICU stays, altered mental status, and diminished post-ICU quality of life. This randomized clinical trial with a total of 190 mechanically ventilated patients enrolled and maintained on protocol will address the following Specific Aims.
The primary aim is to determine the efficacy of SMST compared to nurse-administered sedative therapy on anxiety, duration of mechanical ventilation, and presence of delirium in mechanically ventilated patients (MVPs).
The secondary aim is to compare level of arousal and sedative exposure in mechanically ventilated patients (MVPs) randomized to SMST to those MVPs receiving nurse-administered sedative therapy. The investigators hypothesize that SMST patients will be easily arousable, more alert, and exposed to less sedation than those who receive nurse-administered sedative therapy.
Exploratory aims are to compare post-ICU outcomes (physical/functional status, psychological well-being, and health-related quality of life) and recall of ICU experiences between MVPs randomized to SMST and those receiving nurse-administered sedative therapy.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||228 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Efficacy of Self-management of Sedative Therapy by Ventilated ICU Patients|
|Actual Study Start Date :||November 2016|
|Estimated Primary Completion Date :||December 2023|
|Estimated Study Completion Date :||July 2024|
No Intervention: Control
These patient will get usual care - sedation administered by ICU Nurses as deemed necessary by primary care team
These patients will receive a basal intravenous infusion of medication (Dexmedetomidine) and have access to self-administered sedation medication (Dexmedetomidine) for anxiety.
Patient will receive a maintenance intravenous infusion of medication (Dexmedetomidine) and have access to self-controlled sedation medication (Dexmedetomidine) for anxiety.
Other Name: Precedex
- Changes in anxiety using the 100mm vertical visual analog scale [ Time Frame: 7 days ]Vertical visual analog scale will be used to measure level of state anxiety
- Changes in duration of days receiving mechanical ventilation after study enrollment [ Time Frame: up to 6 months ]Patients' self-management of sedative therapy (SMST) using dexmedetomidine compared to usual sedation practices in mechanically ventilated subjects.
- Changes in delirium using the CAM-ICU tool [ Time Frame: 7 days ]Confusion Assessment Method-ICU (CAM-ICU) will be used as a pre-enrollment delirium screening tool and to measure level of alertness and presence of delirium
- Comparison of level of arousal and alertness using the Richmond Agitation-Sedation Scale [ Time Frame: 7 days ]The Richmond Agitation-Sedation Scale will be used to measure level of arousal and alertness
- Comparison of sedative exposure (sedation frequency + sedation intensity) using electronic health record data of intravenous sedative medications. [ Time Frame: each 24-hour period, up to 7 days ]Frequency of intravenous sedatives medications sums the number of sedative medication doses administered to participant during each 4-hour time period during a 24-hour day. Sedation intensity is a score derived from aggregate dose frequency and dosing of each sedative medications administered to all study participants each 4-hour time period over the 24-hour study day. Scores are summed for the 24-hour period over the 6, 4-hour time blocks to produce a daily sedation intensity score.
- Comparison of post-ICU physical status using the Katz Activities of Daily Living scale [ Time Frame: 3 and 6 months after ICU discharge over the telephone ]Physical status will be assessed by the Katz Activities of Daily Living scale to assess basic physical abilities like bathing, feeding with 6 questions
- Comparison of post-ICU functional status using the Functional Activities Questionnaire [ Time Frame: 3 and 6 months after ICU discharge over the telephone ]Functional status will be assessed by the Functional Activities Questionnaire that contains 10 questions that assess instrumental activities of daily living such as cooking, driving, managing finances.
- Comparison of post-ICU psychological well-being status using the Patient Health Questionnaire [ Time Frame: 3 and 6 months after ICU discharge over the telephone ]Psychological well-being will be assessed by the Patient Health Questionnaire is a 9-item tool that tracks symptoms of major depression
- Comparison of post-ICU psychological well-being status using the Posttraumatic Stress Disorder Checklist Event Specific scale [ Time Frame: 3 and 6 months after ICU discharge over the telephone ]Psychological well-being will also be assessed with the Posttraumatic Stress Disorder Checklist Event Specific toll to measure symptoms of posttraumatic stress disorder.
- Comparison of post-intensive care unit health-related quality of life using the Short-Form 36 [ Time Frame: 3 and 6 months after ICU discharge over the telephone ]Post-intensive care unit health-related quality of life will be assessed by the Short-Form-36
- Comparison of immediate post-extubation recollections of ICU using the Intensive Care Experience questionnaire [ Time Frame: 24 to 48 hours after extubation, 3 and 6 months after ICU discharge over the telephone ]Immediate post-extubation recollection of ICU experiences
- Relationships among cognitive experiences using the Confusion Assessment Method-ICU and awareness using the Richmond Agitation-Sedation Scale with mechanical ventilation complications of device disruption or self-extubation [ Time Frame: 24 to 48 hours after extubation ]Relationships among cognitive experiences, awareness, and mechanical ventilation complications
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Subject is acutely mechanically ventilated during the current hospitalization.
- Subject is currently receiving a continuous intravenous infusion of a sedative/opioid medication(s) or has received at least one intravenous bolus dose of a sedative/opioid medication in the previous 24 hours (fentanyl, hydromorphone, ketamine, morphine, midazolam, diazepam, lorazepam, propofol, haloperidol, dexmedetomidine).
- Subject must pass pre-Patient-Controlled Sedation (PCS) screening test and be assessed Richmond Agitation-Sedation Scale (RASS) -2 to +1
- Subject Age ≥ 18 years
- Subject or their proxy is capable of providing informed consent
- Aggressive ventilatory support or prone ventilation.
- Hypotension (systolic blood pressure < 85 mmHg) requiring a vasopressor at a dose greater than norepinephrine or epinephrine 0.15 mcg/kg/min or vasopressin > 2.4 units per hour. Subjects will be excluded if they require more than one continuous infusion of a catecholamine vasopressor medication simultaneously. Subjects will be excluded if the vasopressor dose was higher than norepinephrine or epinephrine 0.15 mcg/kg/min, vasopressin > 2.4 units per hour, phenylephrine >3 mcg/kg/min, dopamine >10 mcg/kg/min or dobutamine at any dose in the prior 6 hours. If dopamine is being used to increase heart rate, rather than as a vasopressor for hypotension, subject will be excluded.
- Second or third degree heart block or bradycardia (heart rate < 50 beats/min).
- Paralysis or other condition preventing the use of push button device
- Positive pregnancy test or lactation
- Acute hepatitis or liver failure (direct bilirubin >5 mg/dL)
- Acute stroke or uncontrolled seizures.
- Acute myocardial infarction within 48 hours prior to enrollment.
- Severe cognition or communication problems (such as coma, deafness without signing literacy, physician-documented dementia)
- Assessed RASS -3, -4, -5 or RASS +2,+3, +4
- Chronic ventilator support in place of residence prior to current hospitalization.
- Imminent extubation from mechanical ventilator support.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02819141
|Contact: Linda L Chlan, RN, PhDfirstname.lastname@example.org|
|Contact: Karen Cavanaugh, RNemail@example.com|
|United States, Minnesota|
|School of Medicine, University of Minnesota||Recruiting|
|Minneapolis, Minnesota, United States, 55455|
|Contact: Craig R Weinert, MD 612-626-4607 firstname.lastname@example.org|
|Principal Investigator: Craig R Weinert, MD|
|Mayo Clinic in Rochester||Recruiting|
|Rochester, Minnesota, United States, 55905|
|Contact: Karen Cavanaugh, RN 507-538-7178 email@example.com|
|Contact: Pamela Peterson, BNS, RN 507-255-0068 firstname.lastname@example.org|
|Principal Investigator: Linda L Chlan, Ph.D., RN|
|Principal Investigator: Craig R Weinert, MD, MPH|
|Principal Investigator: Mary F Tracy, PhD, RN|
|Principal Investigator:||Linda L Chlan, RN, PhD||Mayo Clinic|
|Responsible Party:||Linda L. Chlan, Ph.D., R.N., FAAN, PI, Mayo Clinic|
|Other Study ID Numbers:||
R01HL030881 ( U.S. NIH Grant/Contract )
|First Posted:||June 30, 2016 Key Record Dates|
|Last Update Posted:||February 13, 2023|
|Last Verified:||February 2023|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
Respiratory Tract Diseases
Hypnotics and Sedatives
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Adrenergic alpha-2 Receptor Agonists
Molecular Mechanisms of Pharmacological Action